KC-6860

293T-cMet-KO-cMet Cell Line

×
67872
Home » 293T-cMet-KO-cMet Cell Line

Background of 293T-cMet-KO-cMet Cell Line

cMet (Mesenchymal-epithelial transition factor) , also known as HGFR (Hepatocyte growth factor receptor) or MET, is a receptor tyrosine kinase encoded by the MET gene on chromosome 7q31.2. It is widely expressed in epithelial and endothelial cells. Upon binding its ligand HGF, cMet activates downstream signaling pathways including PI3K-AKT, MAPK, and STAT3, regulating cell proliferation, survival, migration, and morphogenesis. cMet dysregulation through overexpression, amplification, or mutation is implicated in various cancers, including non-small cell lung cancer, gastric cancer, and renal cell carcinoma. cMet amplification is a well-established resistance mechanism to EGFR-TKIs in NSCLC. Several cMet-targeted therapies, including multikinase inhibitors (e.g., cabozantinib) and specific cMet inhibitors (e.g., tepotinib, capmatinib), have been approved or are in clinical development.

Specifications

Catalog NumberKC-6860
Cell Line Name293T-cMet-KO-cMet Cell Line
NCBI/UniProt Accession NumberNM_000245.2
Clone Number10#
Host Cell Line293T-cMET-KO
DescriptionStable 293T cell line with knockout of endogenous cMet and overexpression of exogenous human cMet gene.
QuantityOne vial of frozen cells (≥2×106 cells)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% DMEM + 20% FBS + 10% DMSO
Propagation MediumDMEM + 10% FBS + 1μg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit saturated culture 1:4-1:5 every 2-3 days
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 30 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

The 293T-cMet-KO-cMet cell line was generated using CRISPR/Cas9-mediated knockout of endogenous cMet and a plasmid vector expressing the exogenous human cMet sequence.

Characterization

Figure 1: Characterization of human cMet overexpression in the 293T-cMet-KO-cMet stable clone using FACS.

Figure 2: Characterization of human cMet overexpression in the 293T-cMet-KO stable clone using FACS.

Figure 3: Characterization of human cMet overexpression in the 293T-cMet-KO-cMet stable clone using PCR sequencing.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO2 incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4-1:5 every 2-3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the cell pellet in chilled freezing medium, ensuring a minimum cell density of 3×106 cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

1. Moores, Sheri L et al. “A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.” Cancer research vol. 76,13 (2016): 3942-53. doi:10.1158/0008-5472.CAN-15-2833
2. Machiraju, Devayani, and Jessica C Hassel. “Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients.” Frontiers in oncology vol. 12 1068029. 24 Jan. 2023, doi:10.3389/fonc.2022.1068029
3. Van Herpe, Filip, and Eric Van Cutsem. “The Role of cMET in Gastric Cancer-A Review of the Literature.” Cancers vol. 15,7 1976. 26 Mar. 2023, doi:10.3390/cancers15071976
4. Teng, Lisong, and Jun Lu. “cMET as a potential therapeutic target in gastric cancer (Review).” International journal of molecular medicine vol. 32,6 (2013): 1247-54. doi:10.3892/ijmm.2013.1531
5. Erlmeier, Franziska et al. “cMET: a prognostic marker in papillary renal cell carcinoma?.” Human pathology vol. 121 (2022): 1-10. doi:10.1016/j.humpath.2021.12.007

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.